

# The influence of antiphospholipid antibodies on INR values measured with the CoaguChek XS

No registrations found.

<b>Ethical review</b>	Positive opinion
<b>Status</b>	Pending
<b>Health condition type</b>	-
<b>Study type</b>	Observational non invasive

## Summary

### ID

NL-OMON21805

### Source

NTR

### Brief title

APL-INR

### Health condition

Antiphospholipid syndrome, thrombosis

## Sponsors and support

**Primary sponsor:** Dutch Thrombosis Foundation

**Source(s) of monetary or material Support:** None, investigator initiated study

## Intervention

## Outcome measures

### Primary outcome

The primary objective of this study is to determine discrepancies between INR measurements with CoaguChek and Coagulometer in lupus anticoagulant positive APS patients.

## Secondary outcome

The secondary objective of this study is to investigate which antiphospholipid antibodies correlate with the found INR discrepancies. Furthermore, we will look into the differences within two different groups of APS patients: triple positive APS patients (tested positive for at least lupus anticoagulant, anti-cardiolipin antibodies and anti- $\beta$ 2-glycoprotein I antibodies) and non-triple positive patients (tested positive for at least lupus anticoagulant).

## Study description

### Background summary

Antiphospholipid syndrome (APS) is characterized by recurrent thrombosis or pregnancy complications in patients with persistent antiphospholipid antibodies. Patients with APS receive anticoagulant therapy with vitamin K antagonists (VKA) to prevent recurrent thrombosis. VKA treatment can be monitored with the international normalized ratio (INR), which is based on clotting tests. The optimal therapeutic window for VKA is an INR between 2.0 and 3.0. An INR < 2.0 is associated with an increased risk of thrombosis and an INR > 3.0 is associated with an increased risk of bleeding. Frequent monitoring and, if necessary, VKA dose adaptation, ensures patients receive adequate anticoagulation. Whilst the INR is routinely measured with clotting tests in a diagnostic laboratory, many patients monitor their own INR with Point Of Care (POC) devices. However, antiphospholipid antibodies can interfere with clotting reactions. Whereas INR reagents used in diagnostic laboratories are insensitive for interference by antiphospholipid antibodies, there are indications that reagents in POC devices are not, which could lead to false INR values and inadequate anticoagulation. In the current study, we will investigate whether INR values in APS patients measured with the most commonly used POC device in the Netherlands (CoaguChek XS) are similar to the gold standard method used in the UMC Utrecht diagnostic laboratory; the Owren method based on a rabbit brain-derived thromboplastin.

### Study objective

We expect differences in INR values between the CoaguChek and Coagulometer in lupus anticoagulant positive APS patients.

### Study design

1x venepuncture and 1x finger stick per patient

### Intervention

Patients will endure 1 finger stick procedure and 1 venepuncture,

## Contacts

### Public

UMC Utrecht  
Tessa Noordermeer

0629443806

### Scientific

UMC Utrecht  
Tessa Noordermeer

0629443806

## Eligibility criteria

### Inclusion criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:

- Age 18 years and older
- Previously confirmed APS, diagnosed in accordance with the Sydney criteria<sup>22</sup>
- Receiving VKA during at least 3 months
- Willing and be able to understand the study information and sign the informed consent form

### Exclusion criteria

A potential subject who meets any of the following criteria will be excluded from participation in this study:

- None

## Study design

### Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non controlled trial

Masking:	Open (masking not used)
Control:	N/A , unknown

## Recruitment

NL	
Recruitment status:	Pending
Start date (anticipated):	03-05-2021
Enrollment:	80
Type:	Anticipated

## IPD sharing statement

**Plan to share IPD:** Undecided

## Ethics review

Positive opinion	
Date:	20-04-2021
Application type:	First submission

## Study registrations

### Followed up by the following (possibly more current) registration

No registrations found.

### Other (possibly less up-to-date) registrations in this register

No registrations found.

## In other registers

Register	ID
NTR-new	NL9427
Other	METC Utrecht : 21-139

## Study results